Skip to main content
. 2017 Jan;187(1):214–224. doi: 10.1016/j.ajpath.2016.09.010

Figure 3.

Figure 3

The peptide kinesin-derived angiogenesis inhibitor (KAI) inhibits vascular endothelial growth factor receptor 2 (VEGFR2) trafficking to endothelial cell surface by preventing binding of VEGFR2 cargo to KIF13B. A: Competitive binding assay performed in human primary umbilical vein endothelial cells (HUVECs). HUVECs were preincubated with KAI for 1 hour and stimulated with vascular endothelial growth factor (VEGF) (2.2 nmol/L) for 1 hour. Immunoprecipitation (IP) of VEGFR2 with anti-KIF13B antibody was detected with anti-VEGFR2 antibody. B and C: Effects of peptide on VEGFR2 transport to the cell surface after VEGF (2.2 nmol/L) treatment of HUVECs. Data are expressed as means ± SEM (A and B). n = 3 (A); n = 14, 11, and 23 for control, KAI 3 μmol/L, and KAI 10 μmol/L, respectively. ∗P < 0.05 (t-test and one-way analysis of variance). Scale bars = 50 μm (C).